Coya Therapeutics (COYA) announced the launch of the ALSTARS Trial, a Phase 2, randomized, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of COYA 302 for the treatment of ALS. Eligible study participants will be randomized to receive one of two different doses of COYA 302 or placebo in this 24-week, double-blind study. Participants who complete the initial placebo-controlled phase will be invited to enroll in an additional 24-week blinded extension to assess the long-term safety and efficacy of COYA 302. During this extension, all participants will receive COYA 302 at one of the two prespecified doses.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COYA:
- Coya Therapeutics’ COYA 303 shows anti-inflammatory effect in animal study
- Coya Therapeutics’ COYA 302 ALS trial accepted by NEALS research consortium
- Coya Therapeutics Receives $4.2M Milestone Payment
- Coya receives $4.2M milestone payment after FDA approval of IND for Coya 302
- Positive Outlook for Coya Therapeutics Amid Promising Developments and Financial Stability